<DOC>
	<DOCNO>NCT01439568</DOCNO>
	<brief_summary>The purpose trial compare progression free survival LY2510924 + carboplatin + etoposide therapy versus carboplatin + etoposide therapy patient extensive-stage disease small cell lung cancer ( SCLC )</brief_summary>
	<brief_title>A Study LY2510924 Patients With Extensive-Stage Small Cell Lung Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>histologically cytologically confirm extensivestage disease small cell lung carcinoma measurable disease define New Response Evaluation Criteria Solid Tumors ( RECIST ) : Revised RECIST Guideline ( version 1.1 ) prior systemic chemotherapy , immunotherapy , biological , hormonal , investigational therapy SCLC performance status 02 Eastern Cooperative Oncology Group ( ECOG ) scale adequate organ function , include : hematologic : absolute neutrophil ( segmented band ) count ( ANC ) great equal ( ≥ ) 1.5 x 10^9/ liter ( L ) , platelets ≥100 x 10^9/L , hemoglobin ≥9 gram per deciliter ( g/dL ) . hepatic : bilirubin le equal ( ≤ ) 1.5 time upper limit normal ( ULN ) , alkaline phosphatase ( AP ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤3.0 time ULN ( AP , AST , ALT ≤5 time ULN acceptable liver tumor involvement renal : calculated creatinine clearance ( CrCl ) ≥45 milliliter per minute ( mL/min ) base standard Cockcroft Gault formula For woman : Must surgically sterile ( surgical procedure : bilateral tubal ligation ) , postmenopausal ( least 12 consecutive month amenorrhea ) , compliant medically approve contraceptive regimen ( intrauterine device [ IUD ] , birth control pill , barrier device ) 6 month treatment period ; must negative serum urine pregnancy test within 7 day study enrollment , must breastfeed . For men : Must surgically sterile compliant contraceptive regimen 6 month treatment period . estimate life expectancy least 12 week write informed consent prior studyspecific procedure able willing learn selfadminister LY2510924 , caregiver willing learn able administer LY2510924 subcutaneous ( SC ) injection currently enrol , discontinue within last 30 day , clinical trial involve investigational product nonapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study prior treatment carboplatin/etoposide LY2510924 concurrent administration antitumor therapy diagnosis nonsmall cell lung cancer ( NSCLC ) mix NSCLC small cell lung cancer ( SCLC ) prior malignancy SCLC , carcinoma situ cervix , nonmelanoma skin cancer , unless prior malignancy diagnose definitively treat 5 year prior study entry subsequent evidence recurrence . Patients history low grade ( Gleason score ≤6 ) localize prostate cancer eligible even diagnose less 5 year prior study entry serious concomitant systemic disorder , opinion investigator , would compromise patient 's ability adhere study requirement active ongoing infection screen require use systemic antibiotic serious cardiac condition , myocardial infarction within 6 month , angina , heart disease define New York Heart Association Class III IV clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , except individual previously treat central nervous system ( CNS ) metastases , asymptomatic , requirement steroid medication 1 week prior first dose study drug complete radiation 2 week prior first dose study drug . know suspect allergy agent give association trial pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Lung</keyword>
	<keyword>Metastasis</keyword>
</DOC>